As a founding member and former chair of the Department of Bioengineering, possibly no one has enjoyed a better purview on the recent remarkable advances in biotechnology than Stanford's Russ Altman. From genome editing to synthetic biology to cloning, the ethical challenges of the field are almost as great as the therapeutic upsides, and advances often outpace our ability to contend with the ethical aftermath. Listen in as host Russ Altman and policy expert and bioengineer Megan Palmer, of the Center for International Security and Cooperation at Stanford, discuss the challenges that arise when biotechnology is used to solve one problem, but creates others in the process. Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related